Registered number |
Registered number: | |||||||
Balance Sheet | |||||||
as at |
|||||||
Notes | 2023 | 2022 | |||||
£ | £ | ||||||
Fixed assets | |||||||
Tangible assets | 3 | - | |||||
Current assets | |||||||
Debtors | 4 | ||||||
Creditors: amounts falling due within one year | 5 | ( |
( |
||||
Net current assets | |||||||
Total assets less current liabilities | |||||||
Creditors: amounts falling due after more than one year | 6 | ( |
( |
||||
Net assets | |||||||
Capital and reserves | |||||||
Called up share capital | |||||||
Capital redemption reserve | 7 | ||||||
Profit and loss account | |||||||
Shareholder's funds | |||||||
Dr Sam Hedayati | |||||||
Director | |||||||
Approved by the board on |
|||||||
Notes to the Accounts | ||||||||
for the year ended |
||||||||
1 | Accounting policies | |||||||
Basis of preparation | ||||||||
Revenue recognition | ||||||||
Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates, and discounts. The company recognises revenue when: The amount of revenue can be reliably measured; It is probable that future economic benefits will flow to the entity; and specific criteria have been met for each of the company's activities. |
||||||||
Tangible fixed assets | ||||||||
Fixtures, fittings, tools and equipment | over 5 years | |||||||
Stocks | ||||||||
Debtors | ||||||||
Creditors | ||||||||
Business combinations | ||||||||
Business combinations are accounted for using the purchase method. The consideration for each acquisition is measured at the aggregate of the fair values at the acquisition date of assets given, liabilities incurred or assumed, and equity instruments issued by the group in exchange for control of the acquired, plus any costs directly attributable to the business combination. When a business combination agreement provides for an adjustment to the cost of the combination contingent on future events, the group includes the estimated amount of that adjustment in the cost of the combination at the acquisition date if the adjustment is probable and can be measured reliably. |
||||||||
Borrowings | ||||||||
Interest-bearing borrowings are initially recorded at fair value, net of transaction costs. Interest-bearing borrowings are subsequently carried at amortised cost, with the difference between the proceeds, net of transaction costs, and the amount due on redemption being recognised as a charge to the profit and loss account over the period of the relevant borrowing. Interest expense is recognised on the basis of the effective interest method and is included in interest payable and similar charges. Borrowings are classified as current liabilities unless the company has an unconditional right to defer settlement of the liability for at least twelve months after the reporting date. |
||||||||
Share capital | ||||||||
Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis. | ||||||||
Taxation | ||||||||
2 | Employees | 2023 | 2022 | |||||
Number | Number | |||||||
Average number of persons employed by the company | ||||||||
3 | Tangible fixed assets | |||||||
Plant and machinery etc | ||||||||
£ | ||||||||
Cost | ||||||||
Additions | ||||||||
At 31 July 2023 | ||||||||
Depreciation | ||||||||
Charge for the year | ||||||||
At 31 July 2023 | ||||||||
Net book value | ||||||||
At 31 July 2023 | ||||||||
4 | Debtors | 2023 | 2022 | |||||
£ | £ | |||||||
Other debtors | ||||||||
5 | Creditors: amounts falling due within one year | 2023 | 2022 | |||||
£ | £ | |||||||
Trade creditors | ||||||||
Taxation and social security costs | ||||||||
Other creditors | ||||||||
6 | Creditors: amounts falling due after one year | 2023 | 2022 | |||||
£ | £ | |||||||
Bank loans | ||||||||
7 | Capital redemption reserve | 2023 | 2022 | |||||
£ | £ | |||||||
At 1 August 2022 | ||||||||
At 31 July 2023 | ||||||||
8 | Other information | |||||||
RITECHEM PHARMACY LIMITED is a private company limited by shares and incorporated in England. Its registered office is: | ||||||||
277-279 Chiswick High Road | ||||||||
London | ||||||||
W4 4PU |